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Abstract
Background: Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosis (SSc). Annual
screening with echocardiogram (ECHO) is recommended. We present the methodological aspects of a PAH screening
programme in a large Australian SSc cohort, the epidemiology of SSc-PAH in this cohort, and an evaluation of factors
influencing physician adherence to PAH screening guidelines.
Methods: Patient characteristics and results of PAH screening were determined in all patients enrolled in a
SSc longitudinal cohort study. Adherence to PAH screening guidelines was assessed by a survey of Australian
rheumatologists. Summary statistics, chi-square tests, univariate and multivariable logistic regression were used
to determine the associations of risk factors with PAH.
Results: Among 1636 patients with SSc, 194 (11.9%) had PAH proven by right-heart catheter. Of these, 160 were
detected by screening. The annual incidence of PAH was 1.4%. Patients with PAH diagnosed on subsequent screens,
compared with patients in whom PAH was diagnosed on first screen, were more likely to have diffuse SSc (p = 0.03),
be in a better World Health Organisation (WHO) Functional Class at PAH diagnosis (p = 0.01) and have less advanced
PAH evidenced by higher mean six-minute walk distance (p = 0.03), lower mean pulmonary arterial pressure (p = 0.009),
lower mean pulmonary vascular resistance (p = 0.006) and fewer non-trivial pericardial effusions (p = 0.03). Adherence
to annual PAH screening using an ECHO-based algorithm was poor among Australian rheumatologists, with less than
half screening their patients with SSc of more than ten years disease duration.
Conclusion: PAH is a common complication of SSc. Physician adherence to PAH screening recommendations remains
poor. Identifying modifiable barriers to screening may improve adherence and ultimately patient outcomes.
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Background
Systemic sclerosis (SSc) is a multisystem connective tissue
disease (CTD) characterised by vasculopathy and fibrosis
[1]. There is no cure for SSc, leading to significant morbid-
ity, mortality and poor health-related quality of life [2, 3].
Cardiopulmonary manifestations, namely interstitial
lung disease (ILD) and pulmonary arterial hypertension
(PAH), have replaced SSc renal crisis (SRC) as the lead-
ing cause of mortality in SSc [4, 5].
SSc-PAH occurs with a prevalence of 8–12% [6] and is
the second most common cause of PAH after idiopathic
PAH [7]. PAH is characterised by abnormal proliferation,
vasoconstriction and thrombosis of the pulmonary
vasculature, leading to elevated pulmonary vascular re-
sistance (PVR), resulting in right-heart failure and death
[8]. Despite new pulmonary vasodilator therapies that
improve symptoms and survival [9–16], one-year and
three-year survival remains poor (78% and 47%, respect-
ively) [17, 18], less than that of idiopathic and other
connective tissue disease (CTD)-associated PAH [18].
Risk factors for the development of SSc PAH include
anti-centromere antibody, telangiectasia, calcinosis,
oesphageal stricture, sicca symptoms, mild ILD and
digital ulcers [19, 20], although none of these perform
sufficiently well as indicators in the individual patient
and are often inconsistent between studies.
Early recognition of SSc-PAH is difficult as early
disease is clinically silent and the heterogeneous nature
of SSc makes interpretation of fatigue and dyspnoea
challenging [21]. Survival is improved even after adjust-
ment for lead-time bias in SSc-PAH when diagnosed by
screening compared with diagnosis during routine care
[9–14]. Consequently, annual screening with transthoracic
echocardiogram (TTE) and pulmonary function tests
(PFTs) is recommended [22], regardless of the presence or
absence of the aforementioned risk factors, to identify
patients who should undergo right-heart catheterisation
(RHC) to confirm the diagnosis.
Despite the documented benefit of PAH screening,
physician adherence is suboptimal, with one study show-
ing that only 34.7% of patients with SSc had a TTE and
53.1% had PFT in the twelve months prior to PAH
diagnosis [23]. Adherence among Australian physicians
is no better, with over 40% not adhering to annual
screening and even fewer using RHC for PAH diagnosis
[24]. Consequently, the Australian Scleroderma Cohort
Study (ASCS), a longitudinal multi-centre study, was
established in 2007 as a web-based screening platform
for the cardiorespiratory manifestations of SSc.
In this paper, we present the methodological aspects of
establishing the ASCS and the screening algorithm, the
characteristics of patients with SSc with PAH in this cohort
and an evaluation of the factors influencing Australian
rheumatologists’ adherence to screening guidelines.
Methods
Study centres
The ASCS is a nationwide project wherein patients with
SSc are recruited from 13 participating centres across
Australia. SSc experts were invited by a core group of
rheumatologists to form the Australian Scleroderma
Interest Group (ASIG) and to take part in the ASCS
through recruitment of patients and collection of data at
their centres. Physicians who are not at an ASIG centre
and care for patients with SSc are invited to refer
patients for the screening service, while ongoing care
between screening visits remains their responsibility.
Patients
All patients with SSc, defined according to American
College of Rheumatology (ACR)/European League Against
Rheumatism (EULAR) criteria [25] or Leroy/Medsger
criteria [26], and mixed connective tissue disease
(MCTD), as originally described by Sharp et al. [27], are
eligible for enrolment. Patients provide written informed
consent for collection of de-identified data, chart review,
and storage of serum and DNA for future studies. All
human research ethics committees of the participating
sites have approved ASCS.
Data collection and database
Comprehensive demographic and disease-related data are
collected annually and entered into a custom-made data-
base hosted by St. Vincent’s Hospital Melbourne using a
remote secure access token. A log is kept of all users and
the database is backed up daily. Logic checks are used to
detect errors in data entry and incomplete entries.
Screening algorithm for early detection of PAH
Participation in the ASCS mandates annual application
of a PAH screening algorithm created by a panel of
Australian rheumatologists, cardiologists and respiratory
physicians (Fig. 1) based on the European Society of
Cardiology (ESC)/European Respiratory Society (ERS)
guidelines [28, 29]. According to Fig. 1, investigations
are recommended for symptomatic patients with low
probability of PAH, and irrespective of symptoms for
patients with moderate or high probability of PAH [30].
Clinical decision support tool
If any value falls outside a predetermined range for
systolic pulmonary arterial pressure (sPAP) on TTE, dif-
fusing capacity of the lung for carbon monoxide (DLCO)
corrected for haemoglobin, and/or forced vital capacity
(FVC) according to the screening algorithm, an email to
the treating physician is automatically generated, indicat-
ing why the alert has been triggered and recommending
a course of action. If the physician chooses not to follow
the algorithm he/she must justify this decision.
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Adherence to published recommendations for annual
PAH screening
Non-ASIG physicians’ screening practices and adherence to
published recommendations for PAH screening [24, 28, 29]
were assessed by means of a cross-sectional survey
(Additional file 1: Table S1 using survey monkey circulated
through the Australian Rheumatology Association follow-
ing the establishment of ASCS in 2007. The survey
addressed existing screening practices based on SSc disease
subtype and disease duration (early or late defined as <10
or ≥10 years from the first non-Raynaud’s disease manifest-
ation, respectively), barriers to screening encountered by
physicians and suggestions for streamlining screening.
Statistics
For the purpose of statistical analysis, de-identified
aggregated data are exported in.txt and.xml format.
Characteristics of patients in the study are presented as
mean (standard deviation (SD)) or number (percentage).
We compared dichotomous variables using the chi-
square test. Continuous variables were compared using
the t test for normally distributed data and the Wilcoxon
rank-sum (Mann-Whitney) test for non-parametric data.
All-cause mortality was used for survival analyses.
Kaplan-Meier (K-M) curves were used to estimate
survival in patients with SSc-PAH diagnosed at first
screen versus subsequent screen. The date of PAH diag-
nosis on RHC was considered the baseline from which
survival was calculated. Log-rank and Wilcoxon tests
were used to compare survival curves.
Results
Recruitment
A total of 1636 patients were recruited into ASCS from
July 2007 to July 2016 (census date). Recruitment
comprised new referrals from general practitioners for
comprehensive specialist management, and from rheu-
matologists requesting the PAH screening service only.
The number of patients recruited, relative to the
predicted prevalence of SSc in Australia [31, 32] and
Fig. 1 Australian Scleroderma Cohort Study algorithm for screening for pulmonary hypertension. ANA antinuclear antibody, ENA extractable
nuclear antibody, CXR chest radiograph, ECG electrocardiogram, TTE transthoracic echocardiogram, PFT pulmonary function test, 6MWT six-minute
walk test, PAH pulmonary arterial hypertension, sPAP systolic pulmonary arterial pressure, DLCO diffusing capacity of the lung for carbon monoxide
corrected for haemoglobin, RHC right-heart catheterization, HRCT high-resolution chest computed tomography, V/Q ventilation perfusion, CTPA
computed tomography pulmonary angiography
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population data from the Australian Bureau of Statistics
[33] were estimated.
Patient characteristics and follow up
Of the 1636 patients, 1243 (75.9%) had been seen within
the 18 months before the census date and were consid-
ered “current” (Table 1). The period of 18 months was
selected to allow for delays in data entry. Patient charac-
teristics and follow-up status are summarised in Table 1.
Patients with limited disease (lcSSc) were older at
recruitment than patients with diffuse disease (dcSSc)
(58.8 ± 12.2 vs 53.1 ± 13.1 years, p < 0.001) with longer
disease duration from first non-Raynaud’s clinical mani-
festation (12.2 ± 10.8 vs 8.1 ± 8.7 years, p < 0.001). ILD
was more prevalent in the patients with dcSSc (40.9% vs
21.1%) but there was no significant difference in the
prevalence of PAH (10.1% vs 12.7%, p = 0.40) (Table 2).
In total, 232 patients (14.2%) were diagnosed with
pulmonary hypertension (PH). Of these, 194 patients
(83.6%) had World Health Organisation (WHO) Group I
PAH according to the criteria developed in Nice [34], 15
patients (6.5%) had exercise-induced PH, 18 patients
(7.8%) had PH secondary to left ventricular dysfunction
(WHO Group 2 PH) and 5 patients (2.2%) had PH
secondary to ILD (WHO Group 3 PH). Only patients
with WHO Group I PAH were analysed in this study.
At enrollment, 34 (2.1%) patients had previously been
diagnosed with PAH and 122 (7.5%) were diagnosed at
their first contact with ASCS. Among the latter, 89
(72.9%) had SSc disease duration of ≥4 years and the
date of their last TTE was 1.6 ± 4.6 years before enroll-
ment to ASCS, highlighting a lack of adherence to
annual PAH screening in the community.
Outcomes of screening in the ASCS
A total of 4326 screening visits were analysed, to deter-
mine the success of, and adherence to the PAH screen-
ing algorithm (Table 3). Only patients not previously
diagnosed with PAH were included. At the first screen-
ing visit, sufficient data to apply the screening algorithm
were available for 1363 patients. Of these, 101 patients
(7.4%) were at high risk of PAH, 121 patients (8.9%) at
moderate risk, 358 patients (26.3%) at low risk and 470
patients (34.5%) at no increased risk based on TTE and
PFT results. The number of patients with no tricuspid
regurgitation (TR) on TTE, and hence inestimable sPAP,
was high at 313 (22.9%).
At the first screening visit, 157 of the 580 (27.1%)
patients at low (38/358), moderate (36/121), or high
(83/101) risk of PAH underwent RHC. WHO Group 1
PAH was diagnosed in 122 patients (8.9% of the cohort),
including 4 of 19 (21.0%) patients with a normal TTE and
10 of 24 patients (41.7%) with a missing sPAP on TTE due
to lack of a TR jet. The patients in the latter two groups
were referred for RHC due to reduced exercise cap-
acity and/reduced DLCO. Only 4% of the patients
with no TR were referred for RHC but 36.8% of these
Table 1 Characteristics of patients recruited up to July 2016
(n = 1636)
Characteristic Number (%) or mean ± SD
Patient number 1636







Age at recruitment, mean ± SD, years 57.2 ± 12.8
Disease duration at recruitmenta, years 10.9 ± 10.2
Recruited within 4 years of first
non-Raynaud’s feature
435
Age at diagnosis of PAH if present, years 62.9 ± 11.1






















ANA positive (n = 1508) 1418 (94.0%)
Anti-centromere (n = 1497) 673 (44.9%)
Anti-Scl70 (n = 1483) 205 (13.8%)
Anti-RNAP (n = 794) 125 (13.1%)
aDisease duration from first non-Raynaud manifestation. Numbers of variables
analysed (n =) are included in each section of the table to acknowledge any missing
data. Patient status: current patients were defined as being seen in the last 2 years,
withdrawn patients have withdrawn their consent from participating in
the database and lost to follow up is defined as patients who, despite
multiple attempts, we have been unable to contact for >18 months. PAH
pulmonary arterial hypertension, MCTD mixed connective tissue disease, ANA
antinuclear antibody, Anti-RNAP anti-RNA polymerase
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were diagnosed with WHO Group 1 PAH. At the
physician’s discretion and based on other indicators
such as patient symptoms and TTE parameters,
patients whose initial RHC was negative for PAH
were considered for future RHC.
The screening algorithm correctly identified patients
at increased risk of PAH and stratified them by level of
risk. The higher the probability of PAH, the more likely
PAH was to be identified on RHC (Table 3). A new
diagnosis of WHO Group I PAH was made in 160
patients from 4326 (3.7%) screening visits (115/1122
with lcSSc, 32/377 with dcSSc and 10/83 with MCTD),
giving a prevalence of PAH of 11.8% (10.3% in lcSSc,
8.5% in dcSSc and 12.0% in MCTD). The annual preva-
lence of PAH was 1.4% (1.2% in lcSSc, 0.9% in dcSSc,
0.4% in MCTD). All patients were treated with specific
PAH therapy.
Characteristics of patients with PAH
Patients with PAH were significantly older than patients
without PAH (63.1 vs 56.3 years, p < 0.001), had longer
disease duration (13.6 vs 10.4 years, p < 0.001) and were
in WHO Functional Class III/IV (85.0% vs 21.7%, p < 0.001)
(Table 4). Clinical manifestations and autoantibody status
are summarised in Table 4.
Characteristics of patients with PAH diagnosed on first
screen compared with patients whose PAH was
diagnosed on subsequent screens
To assess whether the ASCS screening programme
succeeded in detecting PAH at an earlier stage, we divided
our PAH cohort into those patients whose PAH was de-
tected on first screening and those whose PAH was
detected on the second or subsequent screen (Table 5).
We believe that PAH detected on first screen were
likely to be a “delayed diagnosis” in patients who were
referred to ASCS due to symptoms or clinical suspicion
of PAH, whereas PAH detected on subsequent screens
was more likely to be an “incident” PAH identified on
earlier screening.
Patients diagnosed with PAH on subsequent screens
compared with first screen were more likely to have
dcSSc (35.1% vs 15.9%, p = 0.03), be in a better WHO
functional class (54.1% vs 75.9% in Class III, 5.4% vs
16.2% in Class IV, p = 0.01) and have less advanced
PAH at diagnosis evidenced by lower mPVR (3.8 vs
5.5, p = 0.005), higher mean 6MWD (340.6 vs 295.9,
p = 0.05), lower mPAP (32.5 vs 38.2, p = 0.005), and fewer
non-trivial pericardial effusions (2.7% vs 16.0%, p = 0.03).
PAH treatment with combination therapy and anticoa-
gulation therapy was prescribed at a similar rate in those
diagnosed at subsequent screens (36.8% and 28.9%,
respectively) and those diagnosed at first screen (32.1%
and 26.8%, respectively). Three-year survival from the
time of PAH diagnosis was better in those diagnosed on
subsequent screen compared with those diagnosed at first
screen as outlined in Fig. 2 (94.7% vs 42.7%, p < 0.001) and
mean time to death was longer in those diagnosed with
PAH on subsequent screens compared with those diag-
nosed at first screen (4.7 ± 2.3 vs 2.3 ± 2.3, p < 0.001). PAH
was the direct cause of death in 100% of patients
diagnosed on subsequent screen and in 92.7% of those
diagnosed on first screen (p = 0.40).
Adherence to the ASCS screening algorithm
ASIG physicians’ adherence to PAH screening guidelines
was high with 84.4% of patients undergoing annual
screening over a ten-year period. Despite the screening
algorithm (Fig. 1) mandating that patients at moderate
or high risk of PAH should undergo RHC, only 29.7%
(170/572) had RHC. Even among those in the high prob-
ability group, only 59.1% of patients underwent RHC.
Physician justification for not performing RHC predom-
inantly related to their WHO functional class. In 50.5%
of cases, RHC was not performed as the patient was in
WHO Functional Class I (31.6%), or Class II (14.7%) or
was not dyspnoeic (4.2%). In 18.9% of cases, the
physician referred the patient to another specialist for
their opinion, most commonly a cardiologist or respiratory
physician. In 16.8% of cases, the physician was deterred
Table 2 Characteristics of patients with SSc by disease subset
Limited Diffuse P value





Age at recruitment, years 58.8 ± 12.2 53.1 ± 13.1 <0.001
Female 89.5% 74.9% <0.001
Disease durationa (non-Raynaud)
at recruitment, years
12.2 ± 10.8 8.1 ± 8.7 <0.001
Anti-centromere pattern ANA 59.2% 9.6% <0.001
Scl 70 positive 8.9% 31.1% <0.001
RNA polymerase III positive 5.4% 39.6% <0.001
ILD (HRCT scan) 236 (21.11%) 154 (40.9%) <0.001
PAH (RHC) 142 (12.7%) 38 (10.1%) 0.40
Rodnan skin score (highest ever) 7.7 ± 5.4 22.7 ± 9.9 <0.001
Digital ulcers ever 39.6% 60.8% <0.001
Joint contractures ever 28.5% 71.2% <0.001
Renal crisis ever 0.9% 7.7% <0.001
Gastro-oesophageal reflux 80.3% 82.7% 0.29
Anal incontinence 27.9% 25.6% 0.39
ANA antinuclear antibodies, ILD interstitial lung disease, HRCT high-resolution
chest computed tomography, PAH pulmonary arterial hypertension, RHC
right-heart catheterisation
aDisease duration defined as from first non-Raynaud’s disease manifestation.
Disease manifestations are defined as present if ever present from time of
diagnosis of systemic sclerosis (SSc)
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from arranging RHC due to the presence of mild ILD that
they felt accounted for the TTE or PFT result. The
remaining justifications included a plan to repeat the TTE
and/or PFT at a later date (4.2%), patient refusal to have
RHC (2.1%), terminal malignancy (2.1%) and no access to
RHC (1.1%).
Adherence to PAH screening guidelines by Australian
rheumatologists after the establishment of the ASCS
screening programme in 2007
Of 334 non-ASIG Australian rheumatologists, 52
responded to the survey on screening practices and
barriers to screening (Additional file 1: Table S1). The ma-
jority (88.9%) reported screening asymptomatic patients
for PAH regularly. Just over half of the respondents
ordered annual screening for their asymptomatic patients
with early SSc (lcSSc 58.9%, dcSSc 52.6%), with even fewer
screening annually in late disease (lcSSc 38.5%, dcSSc
43.6%). All respondents (100%) would investigate their
patients with symptoms consistent with PAH. In early
symptomatic SSc (with breathlessness or reduced exercise
tolerance), the majority of respondents would screen on a
six-monthly (51.2%) or annual basis (33.6%). In late symp-
tomatic SSc, 38.9% of respondents would screen their
patients six-monthly and 41.2% of respondents would
screen annually. Alarmingly, 17.5% of respondents would
only screen symptomatic patients every two years.
Table 4 Characteristics of patients with SSc by PAH status
PAH No PAH P value
mean ± SD or % mean ± SD or %
Number of patients 209 1283
Age at recruitment, years 63.1 ± 10.4 56.3 ± 12.7 <0.001
Disease duration at
recruitment, yearsa
13.6 ± 11.5 10.4 ± 9.9 <0.001
Female 87.1% 86.2% 0.88








Digital ulcers ever 53.0% 41.9% 0.003
Telangiectasia ever 91.4% 82.4% <0.001
Calcinosis ever 53.3% 34.7% <0.001
Joint contractures ever 45.8% 35.7% 0.007
GORD 45.9% 45.3% 0.48
Bowel dysmotility 27.3% 22.7% 0.15
Anal incontinence 32.1% 25.7% 0.05
WHO Functional Class
Class I 4 (2.1%) 467(39.1%) <0.001
Class II 25 (12.9%) 469 (39.2%)
Class III 106 (54.9%) 238 (19.9%)
Class IV 58(30.1%) 22(1.8%)
NT-pro-BNP 218.9 ± 285.7 75.1 ± 159.8 0.005
PAH pulmonary arterial hypertension, ANA antinuclear antibodies, 6MWD six
minute walk distance, mPAP mean pulmonary arterial pressure, mRAP mean
right atrial pressure, PVR pulmonary vascular resistance, GORD gastro-
oesphageal reflux disease, WHO World Health Organisation, NT-pro-BNP N-
terminal pro b-type natriuretic peptide
aDisease duration defined as from first non-Raynaud’s disease manifestation
Disease manifestations defined as present if ever present from systemic
sclerosis (SSc) diagnosis
Table 5 Comparison of demographic, clinical and haemodynamic
characteristics of patients with PAH diagnosed at first screen and
PAH diagnosed at subsequent screens





mean ± SD or % mean ± SD or %
Number of patients 122 38
Age at PAH
diagnosis
63.9 ± 11.0 62.7 ± 9.5 0.56
Disease duration
at PAH diagnosis
13.4 ± 12.8 14.6 ± 8.7 0.62
Female 96 (85.7%) 32 (84.2%) 0.82
Disease subtype
Limited 81 (75.7%) 23 (62.2%) 0.03
Diffuse 17 (15.9%) 13 (35.1%)
MCTD 9 (8.4%) 1 (2.7%)
Status
Alive 54 (48.2%) 26 (68.4%) 0.03
Dead 55 (49.1%) 10 (26.3%)
Withdrawn 3 (2.7%) 1 (2.6%)
Unable to contact 0 (0%) 1 (2.6%)
Follow up, years 3.3 ± 2.4 5.9 ± 1.9 <0.001
WHO class at PAH diagnosis
Class I 4 (4.0%) 0 (0%) 0.01
Class II 16 (16.2%) 15 (40.5%)
Class III 63 (75.9%) 20 (54.1%)
Class IV 16 (16.2%) 2 (5.4%)
6MWD at PAH
diagnosis
295.9 ± 118.3 340.6 ± 115.6 0.05
mPAP on RHC 38.2 ± 11.4 32.5 ± 8.3 0.005
mRAP on RHC 9.7 ± 8.5 8.4 ± 3.9 0.40
PVR on RHC 5.5 ± 3.1 3.8 ± 1.7 0.005
CI on RHC 2.9 ± 1.6 2.9 ± 0.7 0.87
Pericardial effusion 16 (16.0%) 1 (2.7%) 0.03
Probability of PAH
PAH pulmonary arterial hypertension, MCTD mixed connective tissue disease,
WHO World Health Organisation, 6MWD six-minute walk distance, mPAP mean
pulmonary arterial pressure, RHC right-heart catheterization, mRAP mean right
atrial pressure, PVR pulmonary vascular resistance, CI cardiac index, NT-pro-BNP
N-terminal pro b-type natriuretic peptide
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Explanations for not following guidelines for PAH screen-
ing included cost of screening (60%) and concerns about
how to interpret the results (80%). In order to improve
screening, 50% of respondents felt that they required better
guidelines for the selection and frequency of screening
tests, 44.7% wanted a reminder system, 42.1% wanted
guideline simplification but only 31.6% felt that access to an
experienced screening centre would be helpful. If reim-
bursed by Medicare Australia, 76.3% of respondents would
consider the use of a blood test such as N-terminal pro B-
type natriuretic peptide (NT-pro-BNP) a major advance.
Discussion
We present the ASCS as a model of multi-centre web--
based data collection and decision support for applying
a PAH screening algorithm in patients with SSc. Be-
tween 2007 and 2016, 1636 patients with SSc were re-
cruited, an estimated 30.9% of all Australian patients
with SSc based on a prevalence of 20 per 100,000 people.
As Australia has such sparse population density and SSc is
a low-frequency disease, such multicentre collaborations
are required in order to recruit and retain sufficient pa-
tients for a longitudinal observational study.
The patient characteristics of our cohort are compar-
able to those of other large multi-centre cohorts indicat-
ing that a representative sample is being recruited [35].
As a result of screening, 160 patients were diagnosed
with PAH over a ten-year period, providing an annual
PAH of 1.4%, consistent with that of the French ItinerAIR-
Sclerodermie Study of 0.6% [36] and a prevalence of 11.8%
consistent with worldwide data [13, 36–39].
As in other cohorts [40, 41], patients with PAH were
older, had longer disease duration from the first non-
Raynaud’s clinical manifestation, were more likely to be
anti-centromere (ACA)-positive and to have digital ul-
cers, telangiectasia, calcinosis and joint contractures
compared to those without PAH. Patients with PAH
detected on the second or subsequent screen were more
likely to have dcSSc, be in a better WHO Functional
Class at PAH diagnosis and have less advanced PAH,
which is consistent with the French data [36] but different
from the classical teaching that PAH more commonly
develops in patients with lcSSc [42].
Additionally, patients with PAH diagnosed on subse-
quent screen compared with first screen had signifi-
cantly improved survival (p < 0.001) and a longer mean
time to death (4.7 ± 2.3 vs 2.3 ± 2.3, p < 0.001), which
may in part be due to lead-time bias. Our one-year and
three- year survival in patients diagnosed with PAH on
subsequent visits are similar to the survival rates in the
PHAROS registry [14], one of the few other studies
evaluating survival in incident SSc-PAH diagnosed on
RHC. These survival rates are higher than those reported
in other registries containing a mixture of patients with
both incident and prevalent SSc-PAH or PAH diagnosed
on TTE rather than RHC [38, 43, 44]. Diagnosis of early
PAH is particularly important as patients with early PAH
can progress rapidly, supporting the need for early
treatment in this patient population [12].
Despite the majority of patients in the ASCS being
screened annually, only 29.7% (170/572) of patients
deemed at moderate or high risk of PAH were referred for
RHC, predominantly due to preservation of functional
class limiting patient eligibility for PBS-funded PAH ther-
apy. Concern about the small but documented risk in-
volved in RHC may also have deterred physicians from
referring for RHC but this information was not specifically
sought. These results highlight external factors that limit
adherence to international screening recommendations.
The number of patients with no TR on TTE, and
hence inestimable sPAP, was high at 21.8%, but consist-
ent with the 20–30% reported in the literature [45]. Only
4% of these patients were referred for RHC, with 36.8%
diagnosed with WHO Group 1 PAH. This highlights the
need for a non-TTE dependent method of PAH screen-
ing and supports the emerging role of NT-pro-BNP,
which is increased in PAH and in those at increased risk
[46]. This test is not currently reimbursed for this indi-
cation in Australia and thus is not often performed.
Since the establishment of ASCS in 2007, Australian
rheumatologists’ adherence to screening guidelines has
improved, with 88.9% of physicians regularly screening
asymptomatic patients with SSc for PAH compared with
55.8% previously [29]. Of those who did not perform
TTE for PAH screening, 50% reported this was due to
difficulty assessing the right heart pressures with TTE.
Referral of these patients to a tertiary screening centre
may overcome this obstacle. To our knowledge, there
have been no other studies addressing physicians’ perceived
barriers to SSc-PAH screening.
Fig. 2 Survival in systemic sclerosis (SSc) with pulmonary arterial
hypertension (PAH) according to the screening visit when the
diagnosis was made (first vs subsequent)
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Limitations to our study include the potential for lead-
time and length-time bias to impact on the survival
benefit seen in PAH detected with screening. However,
patients detected by screening were functionally im-
paired at the time of diagnosis and were all commenced
on PAH therapy, indicating that their physician felt that
their PAH required treatment. Our data analyses were
conducted in patients who underwent all procedures
listed in our screening algorithm; therefore, the inci-
dence of PAH in our study may be an underestimate,
although consistent with the literature. Additionally,
only 15.6% of non-ASIG Australian rheumatologists
responded to our survey on PAH screening adherence.
Therefore these particular results may not be a true
reflection of rheumatologists nationwide.
Conclusion
SSc-PAH is a tragic consequence of SSc, which despite
advances in therapy, is the leading cause of SSc-related
death. Screening with a web-based algorithm can iden-
tify patients with earlier PAH and improve outcomes.
Identifying modifiable barriers to screening may improve
adherence and ultimately patient outcomes.
Additional file
Additional file 1: Table S1. Cross-sectional survey of physician adherence
to PAH screening recommendations. (DOC 97 kb)
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